TRANSPIRE: A Prospective Cohort Study of Lung Injury After Hematopoietic Stem Cell Transplant in Children.
TRANSPIRE:儿童造血干细胞移植后肺损伤的前瞻性队列研究。
基本信息
- 批准号:10472509
- 负责人:
- 金额:$ 145.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:10 year oldAddressAdultAffectAllogenicAnatomyBiologicalBiological MarkersBiological TestingBiopsyBronchiolitis ObliteransBronchoalveolar Lavage FluidBronchoscopyCalendarChildChildhoodClinicalClinical DataCohort StudiesCollectionComplicationDataData CollectionDiagnosisDiagnosticDiseaseEarly DiagnosisEnrollmentEtiologyEvaluationEventFailureFreezingFrequenciesFunctional disorderFundingFutureGeneticGuidelinesHematological DiseaseHematopoietic Stem Cell TransplantationHomeImageImpairmentIncidenceInflammationInfrastructureInjuryInvestigationIrrigationKnowledgeLiquid substanceLungLung TransplantationLung diseasesMagnetic Resonance ImagingMarrowMethodsMolecularMonitorMorbidity - disease rateMulticenter StudiesNon-MalignantOscillometryOutcomePathologicPathologyPediatric cohortPerformancePeripheral Blood Mononuclear CellPhenotypePlasmaPoliciesPreparationPreventionPreventiveProspective cohort studyProteomicsPulmonary Function Test/Forced Expiratory Volume 1Pulmonary PathologyPulmonary function testsRare DiseasesRecoveryRegimenResearch PersonnelResourcesRetrospective StudiesRiskRisk FactorsSamplingScheduleScreening procedureSeriesSerumSickle Cell AnemiaSigns and SymptomsSiteSlideSpirometryStandardizationStem cell transplantSurvival RateTechniquesTeenagersTestingThalassemiaTherapeuticTimeTissuesTransplant RecipientsTransplantationUnited States National Institutes of Healthbaseclinical phenotypeclinical riskcohortdiagnostic strategyemerging pathogenexhaustimprovedinnovationlung injurymortalitynew therapeutic targetnovelnovel diagnosticsnovel strategiesoptimal treatmentsphenotypic datapredictive markerprospectiveprospective testpulmonary functionresponsescreeningside effectsmall airways diseasesuccesstargeted agenttherapeutic targettransplant centerstreatment response
项目摘要
Project Summary
Hematopoietic stem cell transplant (HSCT) is increasingly used for non-malignant hematologic
disorders such as sickle cell anemia and marrow failure, and complications of HSCT are more
prevalent and important as causes of long term morbidity. Improved diagnosis and treatment
and treatment are urgent issues. Lung injury is frequent after HSCT, with as many as 15% of
children transplanted having reduced FEV1, later leading to overt bronchiolitis obliterans (BO)
which is associated with high morbidity and mortality. Diagnosis of BO in adults depends on
spirometry, and evidence suggests that early diagnosis may improve chances of recovery of
lung function and survival. Small children, and even older children and teenagers who feel
unwell and are uncooperative, are unable to perform spirometry, meaning that lung impairment
is “invisible” until severe and clinically manifest. Progress in improving lung outcomes of HSCT
in children has been hindered by lack of diagnostic strategies, and by the need for a large group
of cases to allow testing of biological, pathological and diagnostic hypotheses to advance the
field. We propose assembling a prospective cohort study of all children receiving HSCT at 6
major US transplant centers. We will perform standardized prospective testing of lung function
and clinical data collection in all children in the cohort, to determine the frequency, clinical
phenotypes and risk factors for BO (Specific Aim 1). BO is a rare disease so progress will not
be made absent a multi-center cohort study that uniformly defines clinical phenotype and
prospectively collects samples, allowing retrospective study of early molecular events that
predict later disease. In Specific Aim 2 we will collect calendar and event-driven biological
samples, including serum, plasma, peripheral blood mononuclear cells and bronchiolar lavage
fluid, which will be stored and used to identify biomarkers of onset of BO and of response to
therapy. Moreover, we will collect pathological samples that will be analyzed using a pre-
existing rare lung disease pathology platform to identify genetic and anatomic changes that
define BO. Lastly, in Specific Aim 3 we will test and disseminate novel lung testing strategies,
including innovative imaging, to address the critical clinical challenge of late diagnosis of lung
impairment in children. We provide examples of essential biological studies that can only be
performed using the resources of the cohort, for which we will seek additional R01 funding.
Taken together, this cohort study can fundamentally change the paradigm of lung injury after
transplant and provide a platform for testing preventive and therapeutic treatments.
项目摘要
造血干细胞移植(HSCT)越来越多地用于非恶性血液病。
镰状细胞性贫血和骨髓衰竭等疾病以及HSCT的并发症较多
作为长期发病率的原因普遍且重要。改善诊断和治疗
治疗是一个紧迫的问题。HSCT后肺损伤频繁,高达15%的HSCT患者发生肺损伤。
接受移植的儿童FEV 1降低,随后导致明显的闭塞性细支气管炎(BO)
其与高发病率和死亡率相关。成人BO的诊断取决于
肺量测定,有证据表明,早期诊断可能会提高康复的机会,
肺功能和存活率。小孩子,甚至大一点的孩子和青少年,
不适和不合作,无法进行肺功能测定,这意味着肺损伤
是“看不见的”直到严重和临床表现。改善造血干细胞移植肺部预后的研究进展
由于缺乏诊断策略,以及需要一个大的群体,
的情况下,允许测试生物学,病理学和诊断假设,以推进
领域我们建议对所有6岁时接受HSCT的儿童进行前瞻性队列研究,
美国主要移植中心我们将对肺功能进行标准化的前瞻性测试
收集队列中所有儿童的临床数据,以确定频率、临床
BO的表型和风险因素(特定目标1)。BO是一种罕见的疾病,
缺乏统一定义临床表型和
前瞻性收集样本,允许对早期分子事件进行回顾性研究,
预测未来的疾病在具体目标2中,我们将收集日历和事件驱动的生物
样本,包括血清、血浆、外周血单核细胞和细支气管灌洗液
液体,其将被储存并用于鉴定BO发作的生物标志物和对
疗法此外,我们将收集病理样本,并使用预-
现有的罕见肺部疾病病理学平台,以确定遗传和解剖学变化,
定义BO。最后,在具体目标3中,我们将测试和传播新的肺部测试策略,
包括创新的成像技术,以应对肺部疾病晚期诊断的关键临床挑战
对儿童的伤害。我们提供的基本生物学研究的例子,只能是
使用队列的资源进行,为此我们将寻求额外的R 01资金。
总之,这项队列研究可以从根本上改变肺损伤的模式,
移植并为测试预防和治疗性治疗提供平台。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Stella Margaret Davies其他文献
Stella Margaret Davies的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Stella Margaret Davies', 18)}}的其他基金
TRANSPIRE: A Prospective Cohort Study of Lung Injury After Hematopoietic Stem Cell Transplant in Children.
TRANSPIRE:儿童造血干细胞移植后肺损伤的前瞻性队列研究。
- 批准号:
10183698 - 财政年份:2021
- 资助金额:
$ 145.37万 - 项目类别:
Randomized trial of viral specific T-cell infusion to prevent viral infection after hematopoietic stem cell transplant.
病毒特异性 T 细胞输注预防造血干细胞移植后病毒感染的随机试验。
- 批准号:
10436897 - 财政年份:2021
- 资助金额:
$ 145.37万 - 项目类别:
Randomized trial of viral specific T-cell infusion to prevent viral infection after hematopoietic stem cell transplant.
病毒特异性 T 细胞输注预防造血干细胞移植后病毒感染的随机试验。
- 批准号:
10616774 - 财政年份:2021
- 资助金额:
$ 145.37万 - 项目类别:
TRANSPIRE: A Prospective Cohort Study of Lung Injury After Hematopoietic Stem Cell Transplant in Children.
TRANSPIRE:儿童造血干细胞移植后肺损伤的前瞻性队列研究。
- 批准号:
10656380 - 财政年份:2021
- 资助金额:
$ 145.37万 - 项目类别:
Randomized trial of viral specific T-cell infusion to prevent viral infection after hematopoietic stem cell transplant.
病毒特异性 T 细胞输注预防造血干细胞移植后病毒感染的随机试验。
- 批准号:
10158643 - 财政年份:2021
- 资助金额:
$ 145.37万 - 项目类别:
Prediction Model for Radiation Sensitivity in Children with Cancer
癌症儿童辐射敏感性预测模型
- 批准号:
7641844 - 财政年份:2009
- 资助金额:
$ 145.37万 - 项目类别:
Prediction Model for Radiation Sensitivity in Children with Cancer
癌症儿童辐射敏感性预测模型
- 批准号:
7894830 - 财政年份:2009
- 资助金额:
$ 145.37万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 145.37万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 145.37万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 145.37万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 145.37万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 145.37万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 145.37万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 145.37万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 145.37万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 145.37万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 145.37万 - 项目类别:
Research Grant